Merck to buy UK biotech Verona Pharma for $10bn

American pharma giant Merck announced on Wednesday that it is to pay $10bn for UK-based respiratory disease specialist Verona Pharma.

Source: Sharecast

Verona Pharma, whose ADR shares trade on the Nasdaq, is being taken over for $107 each, up from Tuesday's closing price of $86.86, causing the share price to surge 21% in early deals on Wall Street.

According to Merck, the acquisition aligns its science-led business development strategy and expands its pipeline and portfolio of treatments for cardio-pulmonary diseases.

Verona is known for its Ohtuvayre treatment (otherwise known as ensifentrine), which is a first-of-its-kind selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), used in the treatment of chronic obstructive pulmonary disease in adults.

Approved by the FDA last summer, Ohtuvayre is said to be the first novel inhaled mechanism for the treatment of COPD in more than 20 years.

“This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ability to execute on our science-led and value-driven business development strategy,” said Merck's chief executive and chair Robert Davis.

“Ohtuvayre complements and expands our pipeline and portfolio of treatments for cardio-pulmonary diseases while delivering near- and long-term growth as well as value for shareholders."

Transferring your account

Transfer your existing ISAs and Share Dealing Accounts and you could save money. In order to transfer, log in to your existing account and complete the online application form. We’ll do the rest for you. It’s free to transfer (we will not charge you). Please check your current provider to see if they have any charges for transferring.

Transfer to us

Merck & Co. Inc. ( MRK )

Isin: US58933Y1055

Exchange: New York Stock Exchange

Sell:

$ 79.27

Buy:

$ 79.29

Change: 1.17 ( 1.50 %)

Date:

01/08/2025 - 20:59

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Bank of Scotland is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

Bank of Scotland Share Dealing Service is operated by Halifax Share Dealing Limited. Halifax Share Dealing Limited. Registered in England and Wales No. 3195646. Registered Office: Trinity Road, Halifax, West Yorkshire HX1 2RG. Authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.